CN111629757A - 治疗癌症的选择性parp1抑制剂 - Google Patents

治疗癌症的选择性parp1抑制剂 Download PDF

Info

Publication number
CN111629757A
CN111629757A CN201980008960.3A CN201980008960A CN111629757A CN 111629757 A CN111629757 A CN 111629757A CN 201980008960 A CN201980008960 A CN 201980008960A CN 111629757 A CN111629757 A CN 111629757A
Authority
CN
China
Prior art keywords
inhibitor
cancer
use according
parp1
selective inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980008960.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·杜尔
D·里德
乌利亚纳·巴什塔诺瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CN111629757A publication Critical patent/CN111629757A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980008960.3A 2018-01-17 2019-01-16 治疗癌症的选择性parp1抑制剂 Pending CN111629757A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800733.6A GB201800733D0 (en) 2018-01-17 2018-01-17 Cancer
GB1800733.6 2018-01-17
PCT/GB2019/050110 WO2019141979A1 (en) 2018-01-17 2019-01-16 Selective parp1 inhibitors to treat cancer

Publications (1)

Publication Number Publication Date
CN111629757A true CN111629757A (zh) 2020-09-04

Family

ID=61256175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980008960.3A Pending CN111629757A (zh) 2018-01-17 2019-01-16 治疗癌症的选择性parp1抑制剂

Country Status (7)

Country Link
US (1) US20210052632A1 (cg-RX-API-DMAC7.html)
EP (1) EP3740238A1 (cg-RX-API-DMAC7.html)
JP (1) JP7364154B2 (cg-RX-API-DMAC7.html)
CN (1) CN111629757A (cg-RX-API-DMAC7.html)
CA (1) CA3087652A1 (cg-RX-API-DMAC7.html)
GB (1) GB201800733D0 (cg-RX-API-DMAC7.html)
WO (1) WO2019141979A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025307A1 (en) * 2021-08-27 2023-03-02 Impact Therapeutics (Shanghai) , Inc Substituted tricyclic compounds as parp inhibitors and use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer
JP2025508714A (ja) * 2022-02-16 2025-04-10 デューク ストリート バイオ リミテッド 医薬化合物
KR20250023494A (ko) * 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
CN116397031A (zh) * 2023-04-06 2023-07-07 重庆医科大学 Prdx1-uhrf2-parp1信号通路在制备治疗肝癌的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US20110190390A1 (en) * 2010-01-05 2011-08-04 Nicole Renee Murray Methods and materials for treating pancreatic cancer
WO2015048718A2 (en) * 2013-09-30 2015-04-02 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
WO2017192740A2 (en) * 2016-05-03 2017-11-09 Galera Labs, Llc Combination therapy for cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US20110190390A1 (en) * 2010-01-05 2011-08-04 Nicole Renee Murray Methods and materials for treating pancreatic cancer
WO2015048718A2 (en) * 2013-09-30 2015-04-02 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
WO2017192740A2 (en) * 2016-05-03 2017-11-09 Galera Labs, Llc Combination therapy for cancer treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AARON S. MANSFIELD等: "Phase I dose escalation study of the PKCi inhibitor", 《ANTI-CANCER DRUGS》 *
JAMIN D. STEFFEN等: "Structural Implications for Selective Targeting of PARPs", 《FRONTIERS IN ONCOLOGY》 *
MARIANNA TRANI等: "Pro-apoptotic effect of aurothiomalate in prostate cancer cells", 《CELL CYCLE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025307A1 (en) * 2021-08-27 2023-03-02 Impact Therapeutics (Shanghai) , Inc Substituted tricyclic compounds as parp inhibitors and use thereof

Also Published As

Publication number Publication date
JP7364154B2 (ja) 2023-10-18
CA3087652A1 (en) 2019-07-25
US20210052632A1 (en) 2021-02-25
JP2021510677A (ja) 2021-04-30
EP3740238A1 (en) 2020-11-25
WO2019141979A1 (en) 2019-07-25
GB201800733D0 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
JP7364154B2 (ja) がんを治療するための選択的parp1阻害剤
JP6763919B2 (ja) Dna−pk阻害剤としての(s)−n−メチル−8−(1−((2’−メチル−[4,5’−ビピリミジン]−6−イル)アミノ)プロパン−2−イル)キノリン−4−カルボキサミドおよびその重水素化誘導体の共結晶
US20040192656A1 (en) Methods and compositions for the treatment of human and animal cancers
EP3697767B1 (en) Compounds and methods for treating cancer
JP2017519019A (ja) mdm2阻害剤の間欠投与
CN115554405B (zh) 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途
CA3110609C (en) 5-acetamidomethyl-oxazolidinone derivatives for use in the treatment of cancer
De Waard et al. Inhibition of fibroblast collagen synthesis and proliferation by levamisole and 5-fluorouracil
BRPI0713013A2 (pt) compostos orgánicos
Roskoski Jr Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer
US20220000911A1 (en) Combination of gold complexes with olaparib or other parp1/2 inhibitors for use in the treatment of cancer resistant to said parp1/2 inhibitors
US11207319B2 (en) Method for the treatment of bladder cancer
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
JP6748704B2 (ja) 抗癌治療剤
UA128539C2 (uk) Чіаураніб для лікування дрібноклітинного раку легенів
Wang et al. Nutrient transporter-oriented nanoinhibitor counteracts intracellular metabolic reprogramming for RT-resistant HCC treatment
JP2022541690A (ja) 癌治療のための併用療法
JP2014513698A (ja) がん治療保護のためのヒ素の使用
CN101155600A (zh) 放射线治疗增强剂
Blank et al. Hypericin targets multiple signaling mediators in cancer cells generating unique, diverse anti-tumoral, anti-metastatic, and anti-angiogenic activities with evidence for clinical applicability
WO2025162173A1 (zh) 治疗经cdk4/6抑制剂治疗后的乳腺癌用途
TW202545514A (zh) 杜洛希酊及化療藥物於製備用於治療或預防癌症之醫藥組成物的用途
CN113456819A (zh) OXPHOS抑制剂作为抗肿瘤药物Alisertib增效剂的应用
CN104302275A (zh) 类固醇反应性皮肤病的治疗方法
Esmaeilzadeh et al. Chemotherapy Drugs in Uterine Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200904

RJ01 Rejection of invention patent application after publication